Tuesday, June 30, 2020 10:52:48 AM
The company just had a new patent published this month, for removing advanced glycation end products (AEG's) from a bodily fluids.
REDUCTION OF ADVANCED GLYCATION ENDPRODUCTS FROM BODILY FLUIDS
http://www.freepatentsonline.com/y2020/0188427.html
There is a lot to adsorb in this patent (no pun intended), but I will try and highlight a few things that stood out to me:
--------------------------------------------------------------
- Advanced glycation end products (AGEs) are proteins or lipids that become glycated as a result of exposure to sugars in the body. They are a bio-marker implicated in aging and the development, or worsening, of many degenerative diseases.
- These degenerative diseases as well as aging are mainly based on a life-long accumulation of molecular damages within molecules, cells and tissues caused by these advanced glycation end products (AGEs).
- High levels of AGEs have been linked with the development of a variety of diseases including diabetes, heart disease, kidney failure, Alzheimer's and macular degeneration.
- There is a need for methods that treat, prevent or low the progression of diseases associated with AGEs.
- (This is where things get interesting) - One application is where blood or other bodily fluid is pumped out of the body, directly through a CytoSorb™ hemoperfusion cartridge where the beads remove AGEs, and the purified fluid is then pumped back into the body. "Other bodily fluids" include saliva, nasopharyngeal fluid, blood, plasma, serum, saliva, gastrointestinal fluid, bile, cerebrospinal fluid, pericardial, vaginal fluid, seminal fluid, prostatic fluid, peritoneal fluid, pleural fluid, urine, synovial fluid, interstitial fluid, intracellular fluid, extracellular fluid, lymph, mucus, or vitreous humor.
- The patent refers to other embodiments (implementations) which address how the sorbent may be formulated - for example, a powder, a tablet, a capsule, a solution, a slurry, an emulsion, a suppository, or in a food substance. The sorbent may be packaged in portable bottles, vials, blister packs, bags, pouches, or other container that allows for either single or multiple dosages. It also refers to other ways the sorbent can be delivered or administered besides extracorporeal - for example given orally, rectally, via a feeding tube, subcutaneous or transdermal delivery, or topical.
--------------------------------------------------------------
If you are not familiar with AGE's, read this article when you have a chance, it explains everything you want to know about AGE's in layman terms:
"AGEs DamAGE Our Bodies"
http://longevityfacts.com/ages-damage-bodies-advanced-glycation-end-products/
Medical science has yet to invent a magic pill or potion that cleans a significant portion of AGEs from the body. There are drugs and enzymes being tested for use against AGEs but it's proving quite difficult as most drugs and enzymes will attempt to block the cell receptors that AGEs utilize to cause damage in the body. Although there is a lot of research with good prospects there is still to my limited research and knowledge no adequate drugs or therapies to get rid of advanced glycation end-products.
I would ask if there are those with a scientific or medical background to read this patent when they have time and also provide additional insights, because on the surface this looks to be an entirely new product that could come out of this and an entirely new market which is just mind boggling.
Recent CTSO News
- STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting • GlobeNewswire Inc. • 04/17/2024 11:00:00 AM
- CytoSorbents to Report Fiscal 2023 Operating and Financial Results • GlobeNewswire Inc. • 03/06/2024 12:00:00 PM
- CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 10:20:45 PM
- Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients • GlobeNewswire Inc. • 01/17/2024 12:15:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/08/2024 08:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:49:02 PM
- CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation • GlobeNewswire Inc. • 12/28/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:35:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:33:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:31:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:30:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 02:15:22 PM
- CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering • GlobeNewswire Inc. • 12/13/2023 02:15:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/11/2023 09:10:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 09:10:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:20:25 PM
- CytoSorbents Reports Third Quarter 2023 Financial and Operational Results • GlobeNewswire Inc. • 11/09/2023 09:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:10:54 PM
- CytoSorbents to Report Third Quarter 2023 Operating and Financial Results • GlobeNewswire Inc. • 10/27/2023 11:00:00 AM
- CytoSorbents to Present at the 8th Annual Dawson James Conference • GlobeNewswire Inc. • 10/05/2023 11:00:00 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM